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Valle Mendoza2,3 & Joaquim Ruiz1
The objective was to develop and characterise in vitro Bartonella bacilliformis antibiotic resistant 
mutants. Three B. bacilliformis strains were plated 35 or 40 times with azithromycin, chloramphenicol, 
ciprofloxacin or rifampicin discs. Resistance-stability was assessed performing 5 serial passages without 
antibiotic pressure. MICs were determined with/without Phe-Arg-β-Napthylamide and artesunate. 
Target alterations were screened in the 23S rRNA, rplD, rplV, gyrA, gyrB, parC, parE and rpoB genes. 
Chloramphenicol and ciprofloxacin resistance were the most difficult and easiest (>37.3 and 10.6 
passages) to be selected, respectively. All mutants but one selected with chloramphenicol achieved high 
resistance levels. All rifampicin, one azithromycin and one ciprofloxacin mutants did not totally revert 
when cultured without antibiotic pressure. Azithromycin resistance was related to L4 substitutions 
Gln-66 → Lys or Gly-70 → Arg; L4 deletion Δ62–65 (Lys-Met-Tyr-Lys) or L22 insertion 83::Val-Ser-
Glu-Ala-His-Val-Gly-Lys-Ser; in two chloramphenicol-resistant mutants the 23S rRNA mutation 
G2372A was detected. GyrA Ala-91 → Val and Asp-95 → Gly and GyrB Glu474 → Lys were detected in 
ciprofloxacin-resistant mutants. RpoB substitutions Gln-527 → Arg, His-540 → Tyr and Ser-545 → Phe 
plus Ser-588 → Tyr were detected in rifampicin-resistant mutants. In 5 mutants the effect of efflux 
pumps on resistance was observed. Antibiotic resistance was mainly related to target mutations and 
overexpression of efflux pumps, which might underlie microbiological failures during treatments.
Bartonella bacilliformis is the causative agent of Carrion’s disease, a biphasic endemic illness of the Andean val-
leys. In the acute stage (the so-called Oroya fever) severe haemolytic anaemia is present, resulting in 40–85% 
of deaths in untreated people and decreases to around 10% if correctly treated1–3. In this stage the presence of 
concomitant infections such as bloodstream Salmonella infections, among others1,4–6, are frequent due to the 
temporal immunosuppression induced by B. bacilliformis7.
Peruvian wart is the chronic non life-threatening phase, characterised by cutaneous proliferative vascular 
lesions, occurring some weeks or months after the acute infection3.
Additionally, the number of asymptomatic carriers is uncertain, although some studies have shown that 45% 
of the inhabitants of endemic areas present evidence of previous contact with the pathogen8.
The usual treatments are chloramphenicol (CHL) or ciprofloxacin (CIP), alone or combined with cepha-
losporins or aminoglycosides in for the acute stage. Rifampicin (RIF) or azithromycin (AZM) are used in the 
chronic stage6,9. Despite the reported ~10% of deaths among patients receiving adequate treatment3, it is widely 
considered that this microorganism has good clinical response to the above mentioned treatments.
The use of antibacterial agents in the treatment of Carrion’s disease has been profuse in recent decades10. 
Moreover, in asymptomatic carriers the microorganisms are also under antibiotic pressure related to the 
treatment of other infections. However, descriptions of antibiotic-resistant B. bacilliformis clinical isolates are 
scarce11,12. To date, only constitutive nalidixic acid resistance and related diminished fluoroquinolone suscepti-
bility have been reported in association with the presence of an Ala as WT amino acids at positions 91 and 85 of 
GyrA and ParC, respectively13,14. These characteristics are extended to other members of the Bartonella genus13. 
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Additionally, relatively high Minimal Inhibitory Concentration (MIC) levels of clindamycin and colistin12, have 
been observed as well as sporadic isolates presenting resistance to CHL or CIP and a trend towards diminished 
susceptibility to aminoglycosides11,16. Moreover, in vitro resistance to different antimicrobial agents, including 
coumermycin, CIP, RIF and erythromycin, has been described17–19. However, these studies were developed using 
either the KC583 or KC584 strain alone, being limited to the analysis of point mutations, and to date, no study has 
determined the role of efflux pump overexpression or the stability of the antibiotic resistance selected.
Analysis of in vitro obtained mutants may provide information in order to better understand antibiotic- 
resistance acquisition and evolution. The aim of this study was to develop and characterise a series of in vitro 
B. bacilliformis antibiotic resistant mutants and determine the presence of target mutations, the role of efflux 
pumps as well as the stability of selected resistance.
Results
Development of antibiotic-resistant mutants. The time required for bacterial lyophilised reactivation 
varied from 5 weeks (strains 57.19 and 57.20) to 9 weeks (strain 57.18). Interestingly, strain 57.18 showed an 
initially different morphology, coinciding with the previously described T1 morphology20, although this reverted 
in the next passage (Fig. 1).
The development of the antibiotic-resistant mutants required approximately 18 months, therefore, 
4 antibiotic-resistant mutants were obtained from each parental strain, one for each antibiotic included in the 
study.
The first antibiotic to generate inhibitory halo 0 mm was RIF, with only 4 passages to obtain confluent growth 
(strain 57.19). However, overall, the antibiotic requiring the least number of passages to generate confluent 
growth was CIP with a mean of 10.6 passages. On the other hand, CHL required > 37.3 passages (Table 1). Thin 
growth was observed inside the halo recorded during the process of mutant selection of 57.20Azm. Thus, after the 
initial 35 passages, most antibiotic-resistant mutants showed confluent growth in the presence of the antibiotic 
disc (inhibitory halo 0 mm) except for two out of three mutants selected with CHL, which presented inhibi-
tory halos of 18 mm (57.18Chl-35) and 32 mm (57.20Chl-35). After 5 additional serial passages (total: 40 passages), 
57.20Chl-40 achieved a halo of 0 mm, while 57.18Chl-40 remained with an inhibitory halo of 18 mm (Fig. 2).
Analysis of MIC levels and stability of resistance. A maximum of 1 dilution difference between the 
MICs at 7 and 14 days was observed. Thus, those obtained at 7 days were used throughout the manuscript.
Analysis of the MIC levels showed that all but 1 mutant achieved MICs up to the E-test detection limit 
> 256 mg/L (AZM, RIF and CHL) and > 32 mg/L (CIP). The exception was the above mentioned 57.18Chl-40 
mutant that reached a CHL MIC level of 4 mg/L (Table 2).
Figure 1. Colony morphology. The photograph shows B. bacilliformis presenting T1 colony morphology20. 
The colony is characterised by a small, translucent round morphology, with a regular edge and a small halo. 
The colonies present a “bubble” in the center of the colony. The morphology was unstable and disappeared after 
reculture.
Number of passages
Strains
Antibiotic 57.18 57.19 57.20 Mean
Azithromycin 10 12 20 14
Chloramphenicol > 40* 32 40 > 37.3
Ciprofloxacin 6 11 15 10.6
Rifampicin 20 4 25 16.3
Table 1.  Number of passages needed to obtain confluent growth. *At the end of 40 passages, in presence of a 
chloramphenicol disc, a halo of 18 mm was observed.
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Interestingly, analysis of the stability of the resistance obtained showed that all RIF selected mutants were 
stable, as were 57.18Azm-5St and 57.18Cip-5St. Two strains (57.18Chl-5St and 57.19Chl-5St) returned to the parental MIC 
levels, while the remaining isolates showed intermediate MICs between parental and final mutant values. In the 
case of mutants 57.19Azm-5St and 57.20Cip-5St at 14 days the presence of colonies within the inhibitory halo were 
observed. Thus, 57.19Azm-5St-WH showed a MIC of AZM of 32 mg/L while 57.20Cip-5St-WH showed a MIC > 32 mg/L 
for CIP (Table 2).
Antibiotic cross resistance. When the mutants were selected with AZM the MICs to other antibiotics gen-
erally increased, while the selection with CHL usually resulted in decreases in other MICs, and in those selected 
with CIP and RIF the results were more variable (Tables 2 and 3).
Target mutations. None of the genes of the parental strains analysed presented differences with respect 
those of the KC583 strain except the amino acid codon change Thr-13 → Ala at L4 protein and Arg-9 → Cys at 
L22 protein.
Figure 2. Evolution of disc diameter halo during serial passages. (A) Azithromycin, (B) Chloramphenicol,  
(C) Ciprofloxacin, (D) Rifampicin. This figure demonstrates the ease with each mutant are selected for each antibiotic. 
The halo diameters (measured in mm) are reported every 5 passages or at the passage in which halo zero was 
obtained. In (B) is clearly visualised the difficulty with which resistance to chloramphenicol (CHL) is developed.
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AZM resistance was related to the presence of alterations in the rplD and rplV genes, encoding the L4 and L22 
proteins, respectively. No mutation was observed in the 23S rRNA gene. Thus 57.18Azm and 57.18Azm-5st showed 
a predicted 4 amino acid deletion (Lys-Met-Tyr-Lys) at L4 protein from codons 62 to 65 (Δ 62–65). Nonetheless, 
close analysis of the spherogram showed the presence of a double sequence from the deletion onwards under 
the majority peaks with in the reading-frame together with a non-deleting rplD (Supplementary Figure 1). 
Meanwhile, in mutants 57.19Azm-35 and 57.19Azm-5st we observed the presence of the L4 amino acid codon 
change Gly-70 → Arg, with a change His-74 → Tyr also being observed in 57.19Azm-5st-WH. The mutant 57.20Azm 
showed the presence of alterations at both the rplD and rplV genes. Thus, the presence of an amino acid codon 
change Gln-66 → Lys was observed in the rplD gene, while a 27 base-pair insertion (leading to the 9 amino acid 
Val-Ser-Glu-Ala-His-Val-Gly-Lys-Ser) was observed at one of the two rplD B. bacilliformis genes after position 83 
(Supplementary Figure 1). Interestingly the 57.20Azm-5St rplD gene showed a double peak which presented a mixed 
population with a partial reversion of the change Gln-66 → Lys.
Regarding quinolone resistance, no mutation was observed in the Topoisomerase IV encoding genes (parC 
and parE). A GyrA amino acid substitution was observed in 2 out of 3 selected mutants, 57.18Cip-35 and 57.20Cip-35 
(Ala-91 → Val and Asp-95 → Gly, respectively), and a GyrB amino acid substitution (Glu-475 → Lys) was 
observed in 57.19Cip-35. The mutations present in 57.18Cip-35 and 57.19Cip-35 were stable and were also observed in 
the mutants 57.18Cip-5St, and 57.19Cip-5St. In the case of 57.20Cip-35 the analysis of the sequence spherogram showed 
the presence of a double peak with two bacterial populations, one with the WT gyrA gene sequence and other 
possessing the aforementioned amino acid codon substitution. This was confirmed by analysing 57.20Cip-5St (pos-
sessing a WT gyrA gene sequence) and 57.20Cip-5St-WH (which maintained the amino acid change Asp-95 → Gly). 
Strain
MIC1 (mg/L)
Mechanisms of Resistance
Fluoroquinolones Macrolides Macr + Amph2 Rifamycins EPIs3
AZM CHL CIP RIF GyrA GyrB ParC ParE L4 L22 23S rRNA RpoB PAβN4 ART5
57.18 0.19 0.38 0.5 < 0.016 wt wt Wt wt wt wt wt wt — —
57.18Azm-35 >256 2 0.75 < 0.016 — — — — Δ 62–65 wt wt — Y Y
57.18Azm-5St > 256 — — — — — — — Δ 62–65 wt wt — — —
57.18Chl-40 < 0.016 4 0.38 < 0.016 — — — — — — wt — Y Y
57.18Chl-5St — 0.125 — — — — — — — — wt — — —
57.18Cip-35 < 0.016 0125 >32 < 0.016 Val91 wt Wt wt — — — — N N
57.18Cip-5St — — > 32 — Val91 wt Wt wt — — — — — —
57.18Rif-35 < 0.016 0.75 0.38 >256 — — — — Arg527 N N
57.18Rif-5St — — — > 256 — — — — Arg527 — —
57.19 < 0.016 0.125 0.38 0.016 wt wt Wt wt wt wt wt wt — —
57.19Azm-35 >256 0.5 0.125 < 0.016 — — — — Arg70 wt wt — N N
57.19Azm-5St 0.5 — — — — — — — Arg70 wt wt — — —
57.19Azm-5St-WH 32 — — — --- — — — Arg70+ Tyr74 wt wt —
57.19Chl-35 < 0.016 >256 0.125 < 0.016 — — — — — — A2372 — N N
57.19Chl-5St — 0.094 — — — — — — — — wt — — —
57.19Cip-35 0.064 0.5 >32 < 0.016 wt Lys475 Wt wt — — — — N N
57.19Cip-5St — — 1.5 — wt Lys475 Wt wt — — — — — —
57.19Rif-35 < 0.016 0.75 2 >256 — — — — — — — Tyr540 N Y
57.19Rif-5St — — — > 256 — — — — — — — Tyr540 — —
57.20 0.064 0.25 0.38 < 0.016 wt wt Wt wt wt wt wt wt — —
57.20Azm-35 >256 0.38 1 < 0.016 — — — — Lys66 83::VSEAHVGKS — — N Y
57.20Azm-5St 2 — — — — — — — Lys66* 83::VSEAHVGKS — — — —
57.20Chl-40 < 0.016 >256 0.25 < 0.016 — — — — — — A2372* — N N
57.20Chl-5St — 0.5 — — — — — — — — wt — — —
57.20Cip-35 0.094 0.25 >32 < 0.016 Gly95 wt Wt wt — — — — N Y
57.20Cip-5St — — 0.38 — Gly95* wt Wt wt — — — — — —
57.20Cip-5St-WH — — > 32 — Gly95 wt Wt wt — — — —
57.20Rif-35 0.094 1 0.047 >256 — — — — — — —
Phe545+ 
Tyr588 N Y
57.20Rif-5St — — — > 256 — — — — — — —
Phe545 +  
Tyr588 — —
Table 2.  MICs and mechanisms of resistance. AZM: azithromycin; CHL: Chloramphenicol; CIP: Ciprofloxacin; 
RIF: Rifampicin. The asterisks indicate the presence of double peaks, suggesting either the presence of a double 
bacterial population or the presence of mutations in one of the two copies of the B. bacilliformis gene. Mutants in 
which cross-resistance to other antibiotics were observed are in underlined font. The final MIC of the antibiotic used 
in the mutant selection is shown in bold. 1Minimal Inhibitory Concentration. 2Macrolides and Amphenicols. 3Efflux 
Pumps Inhibitors. 4Phe-Arg-β -Naphtylamide. 5Artesunate.
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The in silico determination of the hydrophobicity pattern showed an alteration in the presence of GyrA Val-
91, while the presence of GyrA Asn-95 altered both the charge and slightly affected the hydrophobicity pattern 
(Fig. 3).
In the 57.19Chl-35 mutant an alteration in the 23S rRNA gene (G2372A) was detected, which reverted after 5 
passages without antibiotic pressure. The same mutation was also observed in the 57.20Chl-40 mutant, but a double 
peak was observed showing the presence of a double bacterial population, or, more probably, that the mutation 
was only present in one of the two 23S rRNA genes of the B. bacilliformis genome (Supplementary Figure 1).
Finally, the presence of mutations in the rpoB gene was observed in all RIF-selected mutants which were 
also present after the 5 passages without antibiotic pressure, leading to the amino acid changes Gln-527 → Arg 
(57.18Rif-35, 57.18Rif-5St), His-540 → Tyr (57.19Rif-35, 57.19Rif-5St) and Ser-545 → Phe plus Ser-588  → Tyr (57.20Rif-35 
and 57.20Rif-5St). Interestingly, when the rpoB gene in the 57.20 RIF-derived mutant at passage 13 (57.20Rif-13), was 
sequenced, only the presence of the amino acid codon change Ser-588  → Tyr was observed.
Effect of Efflux Pumps Inhibitors (EPIs). The study of the effect of Phe-Arg-β -Napthylamide (PAβ N) and 
artesunate (ART) on normal bacterial growth showed that high PAβ N concentrations (7.5, 10, 20 mg/L) allowed 
bacterial, albeit non normal, growth. Thus, a concentration of 5 mg/L was used in the assays. No effect of ART was 
observed on bacterial growth with 20 mg/L. Additionally, we confirmed the lack of effect on bacterial growth with 
ethanol at the concentration and required volume used.
Both PAβ N and ART had a visible effect on the CHL MIC of 57.18Chl-40, and this effect was also confirmed by 
the increased disc inhibitory halo in the presence of both EPIs. Both EPIs also affected the AZM susceptibility lev-
els of the 57.18Azm-35 mutant. Additionally, ART was found to affect the RIF MIC of 57.19Rif-35, and also enhanced 
the activity of RIF and CIP in 57.20Cip-35 and 57.20Rif-35 mutants respectively (Tables 2 and 4).
Discussion
Currently antimicrobial resistance levels have only been established in a few B. bacilliformis clinical or collection 
isolates11,12,14–16. Information about the mechanisms of antibiotic resistance exhibited by these isolates is very 
scarce and strictly focused on constitutive quinolone resistance13–15. This lack of data, together with the high 
percentage of clinical cure without microbiological elimination described in more than 22% of CIP and up to 
50% of CHL treatments as well as the high-lethality related to the acute illness phase in the absence or delay of 
treatment2,3,21, highlight the need for in vitro information about the ease with which this microorganism devel-
ops resistance and which antibiotic resistance mechanisms are selected. To the best of our knowledge only three 
in vitro studies has been developed to date17–19, and none has determined the stability of the antibiotic resistance 
selected or the role of efflux pump overexpression.
Although the 57.19 strain only needed 4 consecutive passages to develop full resistance to RIF, overall, the 
antibiotic which most easily selected resistant mutants was CIP. This is in accordance with the possession of Ala-
91 and Ala-85 of GyrA and ParC respectively which affect the hydrophobicity pattern of these proteins, impairing 
the interaction of quinolones and acting as a factor favouring the selection of resistance to fluoroquinolones14,22. 
In fact, it has been shown that the frequency of mutation of B. bacilliformis KC583 was 10-fold higher than that 
of Escherichia coli, while only 5 passages were needed to select high CIP-resistant mutants from strain KC58418,19. 
Regarding RIF and AZM, full resistance was obtained after 3 and 4 passages respectively18. There are no previous 
reports on the selection of Bartonella spp. CHL-resistant mutants. In our study, resistance to CHL was consist-
ently the most difficult to obtain. Although this finding is in apparent disagreement with the observed 50% of per-
sistent bacteraemia after CHL treatments21, it might be related to changes at the fitness level as has been observed 
in the presence of specific 23S rRNA gene point mutations in other microorganisms23–25.
The MIC of the mutants selected was higher than that of the parental isolates, achieving high MICs levels with 
all the antibacterial agents tested. This finding shows a worrisome scenario: the feasibility of selecting high anti-
biotic resistant mutants with the 4 main antibiotic families used in the treatment of Carrion’s disease. However, 
only those mutants selected with RIF showed consistent resistance stability, while only 1 out of 3 of CIP or 
MIC 1/ (fold)2
Azithromycin (AZM)3 Chloramphenicol (CHL)3 Ciprofloxacin (CIP)3 Rifampicin (RIF)3
Ab4 57.18Azm-35 57.19 Azm-35 57.20 Azm-35 57.18Chl-40 57.19Chl-35 57.20Chl-40 57.18Cip-35 57.19Cip-35 57.20Cip-35 57.18Rif-35 57.19Rif-35 57.20Rif-35
AZM — — — < 0.016  (< 0.08) < 0.016 (ND)
< 0.016  
(< 0.25)
< 0.016  
(< 0.08)
0.064 
(>4.00) 0.094 (1.47)
< 0.016  
(< 0.08)
< 0.016 
(ND) 0.094 (1.47)
CHL 2 (5.26) 0.5 (4.00) 0.38 (1.52) — — — 0.125 (0.33) 0.5 (4.00) 0.25 (1.00) 0.75 (1.97) 0.75 (6.00) 1 (4.00)
CIP 0.75 (1.50) 0.125 (0.33) 1 (2.63) 0.38 (0.76) 0.125 (0.33) 0.25 (0.66) — — — 0.38 (0.76) 2 (5.26) 0.047 (0.12)
RIF < 0.016 (ND)
< 0.016  
(< 1.00)
< 0.016 
(ND)
< 0.016 
(ND)
< 0.016  
(< 1.00)
< 0.016 
(ND)
< 0.016 
(ND)
< 0.016  
(< 1.00)
< 0.016 
(ND) — — —
Table 3.  Cross resistance levels for the mutants obtained. The cases in which the MIC of the mutant 
decreased with respect to the parental isolate are highlighted in underlined font while those in which the MIC 
increased, (expressed in mg/L) are shown in bold. ND: not-determined. 1Minimal Inhibitory Concentration in 
mg/L. 2Fold: MIC fold increase/decrease compared to parental isolate. When the quotient ranks between 0.5 
and 2 no effect was considered. Values ≥ 2 represent a co-selection of resistance, while values < 0.5 indicate that 
the mutant strain increased its susceptibility levels to the antimicrobial agent analysed. 3Antibiotic used in the 
selection of resistant mutants. 4Antibiotic tested.
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AZM-resistant mutants did not revert either totally or partially. Regarding CHL, all the resistant mutants selected 
reverted, supporting the idea of a high biological cost of the development of CHL resistance. In the same line, the 
presence of double sequences when analysing some of antibiotic target gene sequences may be interpreted in three 
different ways: The survival of original susceptible parental strains, the partial reversion of the mutants obtained 
when antibiotic pressure disappears or the presence of mutations in only one of the gene copies when there is 
more than one. The first possibility is unlikely because of the high susceptibility levels of the parental strains to 
all the antibacterial agents tested (halo diameter > 100 mm) which prevent the survival of the microorganisms 
when the disc was placed on the center of the plate (the maximum possible halo diameter is 50 mm). Meanwhile 
Figure 3. Hydrophobic and charge patterns associated with GyrA amino acid substitutions. (A) Alterations 
in the hydrophobic pattern. Additionally to the amino acid substitutions detected (Ala-91 → Val and Asp-
95 → Gly) the theoretical effect of the presence of Ser-91 also shows the gradual effect on the hydrophobic 
pattern related to the presence of Ser, Ala or Val at position 91. (B) Effect on the charge pattern. This graph only 
shows the effect of Asp-95 and Gly-95 since the presence of Val-91 does not result in charge pattern alterations. 
The (A) comprises the amino acid sequence from amino acids 84 to 99, while in (B) the amino acid sequences 
analysed are from amino acids 70 to 107.
Mutant Antibiotic
Mutant1
Susceptibility level in presence of EPIs
PAβN ART
disc2 MIC3 disc MIC disc MIC
57.18Azm-35 AZM 0 > 256 24 > 256 20 48
57.18Chl-40 CHL 18 4 40 1 48 1.5
57.18Cip-35 CIP 0 > 32 0 > 32 0 > 32
57.18Rif-35 RIF 0 > 256 0 > 256 0 > 256
57.19Azm-35 AZM 0 > 256 0 > 256 0 > 256
57.19Chl-35 CHL 0 > 256 0 > 256 0 > 256
57.19Cip-35 CIP 0 > 32 0 > 32 0 > 32
57.19Rif-35 RIF 0 > 256 0 > 256 0 96
57.20Azm-35 AZM 0 > 256 0 > 256 20 > 256
57.20Chl-40 CHL 0 > 256 0 > 256 0 > 256
57.20Cip-35 CIP 0 > 32 0 > 32 20 > 32
57.20Rif-35 RIF 0 > 256 0 > 256 26 > 256
Table 4. Effect of efflux pump inhibitors (EPIs) on the antibiotic susceptibility levels. ART: Artesunate; 
AZM: azithromycin; CHL: Chloramphenicol; CIP: Ciprofloxacin; RIF: Rifampicin. The samples in which 
the effect of EPIs was visible highlighted in bold. 1Antibiotic susceptibility of mutant isolates at last selection 
passage. 2Disc halo diameter measured in mm. 3Minimal inhibitory concentration by E.-test in mg/L.
www.nature.com/scientificreports/
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the other two possibilities may be considered, and, moreover, are not mutually exclusive. They might underlie the 
high number of microbiological failures, isolation of viable microorganisms from blood, after successful clinical 
treatments21. Moreover, the reversion observed in the 57.20Azm-35 mutant may be related to the slower growth 
described in association with L4 and L22 alterations26. Along this line, the reversion of resistance, the presence 
of double bacteria populations in at least two mutants (one selected with CIP and other with AZM) as well as 
the additional time needed by some of the resistant strains (57.19Azm-5St-WH, 57.20Cip-5st-WH) to grow, support the 
idea that the development of antibiotic resistance has a high biological cost in B. bacilliformis, resulting in the 
dilution of strains carrying specific antibiotic-related mutations within a general antibiotic susceptible bacterial 
population. Similarly, both the loss of biological efficiency and the decrement of virulence after the development 
of antimicrobial resistance have been observed in other microorganisms27,28. However, compensatory mutations 
might result in the development and spread of resistant isolates27,29.
Although non-uniform, cross effects, either increases or decreases, in the MIC levels were observed. These 
alterations might be explained by collateral antibiotic resistance effects that could interfere with normal bacteria 
biochemical processes. Three of antibacterial agents tested act at a ribosome level, while the remaining agent acts 
at the proteins involved in DNA decatenation and duplication. Ribosomal level alterations may differentially 
affect the expression of genes or may have a direct effect on the activity of other agents. In other microorgan-
isms, specific points placed in 23S rRNA and in the ribosomal proteins may result in concomitant resistance 
between CHL and macrolides30,31. Among these, it has been suggested that L4 deletions Δ 65–66 (Trp-Arg) and 
Δ 68–69 (Lys-Gly) leading to macrolide-resistance in Streptococcus pneumoniae also confres low levels of CHL 
resistance. Thus, S. pneumoniae L4 Δ 65–66 has been associated with an increase of the CHL MIC of up to 4-fold 
when cloned in a pan-susceptible S. pneumoniae strain31. Amino acid codons 65 and 66 of S. pneumoniae are 
equivalent to positions 64 and 65 of B. bacilliformis, both included within the Δ 62–65 of 57.18Azm-35 mutant. Thus, 
the role of L4 deletions in the acquisition of the low levels of CHL resistance observed in this mutant (MIC 
2 mg/L, 5.26-fold increases) is plausible, either directly due to alterations in the ribosome conformation affecting 
CHL binding or indirectly due to the possible induction of efflux pump overexpression as discussed below. This 
fact highlights the risk of co-selection of antibiotic resistance during B. bacilliformis treatment.
On the other hand, selection of CHL seems to negatively affect the ability of bacteria to survive in the pres-
ence of other antibiotic agents. This fact may also be related to the above mentioned possible effect on fitness, 
being probably underlain by alterations in the expression or regulation of different bacterial genetic factors. 
Additionally, selection of hypersusceptibility to unrelated antibiotics, such as macrolides, has also been observed 
in relation to specific 23S rRNA mutations32.
Two differences leading to the substitutions Thr-13 → Ala at L4 and Arg-9 → Cys at L22, were observed 
between the parental and KC583 strains. Nonetheless, both substitutions were present in other B. bacilliformis 
genomes. This finding, together with the high antibiotic susceptibility of the parental isolates, suggests the pres-
ence of DNA polymorphisms.
Regarding AZM resistance, in all the cases the presence of alterations at L4 and L22 was found, while no 
mutation at 23S rRNA was observed. This latter finding differs from that described in microorganisms with a low 
number of 23S rRNA gene copies33 and observed in previous studies developed in B. bacilliformis and Bartonella 
henselae18,34,35.
Amino acid changes at L4 and L22, including insertions and deletions, have been described in a series of 
unrelated microorganisms, such as E. coli26,36,37. Regarding Bartonellaceae, the mutations at L4 (Gly-70 → Arg and 
Gly-70 → Arg + His-74 → Tyr) have been previously described in in vitro obtained macrolide-resistant mutants 
of B. henselae35. In E. coli, a series of amino acid changes involving the L4 residues Gln-62 and Gly-66 equivalent 
to B. bacilliformis Gln-66 and Gly-70 have been reported as being involved in the development of AZM resist-
ance26,36. Interestingly, in E. coli substitutions at position Ser-70 (equivalent to B. bacilliformis His-74) have been 
described36, but never alone, as reported by Biswas et al.34, suggesting a minor role of this substitution in the 
development of macrolide resistance.
This is the first report describing insertions and deletions in the L4 and L22 proteins of B. bacilliformis. The 
predicted L4 deletion is located close to the L4 “hot spot” region involved in macrolide resistance in which a dele-
tion of the 2 equivalent later amino acids in macrolide-resistant S. pneumoniae has been reported31, while to the 
best of our knowledge no insertion has been described in equivalent positions in other microorganisms.
Two out of three CHL-resistant mutants (57.19Chl-35 and 57.20Chl-40) presented a G2372A mutation in the 23S 
rRNA gene. The equivalent mutation has previously been involved in CHL resistance in yeasts and E. coli25,38. 
Although in the case of the 57.20Chl-40 mutant double peaks were obtained suggesting either the presence of a 
double bacterial population, or, more probably, the presence of a mutation affecting only one of the two 23S rRNA 
genes. This fact, together with the rapid reversion of this mutation and the slow bacterial growth, which might 
be longer than 2 months in clinical samples cultures10,39, might explain the presence of microbiological failures 
after CHL treatments, contributing to the lack of reports of CHL resistance in clinical isolates. Supporting the 
biological cost of the development of CHL resistance, the equivalent G2447A mutation in E. coli results in both 
resistance to CHL and in retarded growth rates25.
The amino acid alterations observed in two out of three GyrA were located in the classical quinolone-DNA 
Gyrase interaction points, while resistance in the third isolate was related to the presence of mutations in the 
gyrB gene. Up to now, no amino acid change at GyrA position 91 has been described in B. bacilliformis. However, 
alterations at equivalent GyrA position have been extensively described in other quinolone-resistant microor-
ganisms22, including the presence of Val-91, detected both in B. henselae and unrelated microorganisms22,34,40. 
The presence of an Ala in position 83 of the GyrA of E. coli (equivalent to 91 of B. bacilliformis) results in a 
decreased CIP MIC, and intermediate or low-level of nalidixic resistance40–42, while the presence of Val results 
in full fluoroquinolone-resistance as well as in high levels of resistance of nalidixic acid40. These findings may be 
directly related to the different effect on the GyrA hydrophobicity pattern and the subsequent involvement of the 
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ability of quinolones to bind with their targets in relation to the presence of Ser (WT amino acid in E. coli and 
most other microorganisms) Ala or Val residues, as shown in Fig. 3.
Changes at position Asp-95, including Asp-95 → Gly, have been previously described in studies analysing 
quinolone-resistant mutants of B. bacilliformis, B. henselae and Bartonella quintana18,19,43. Changes at equivalent 
position have frequently been reported in other microorganisms22,40. The effect of different mutations is addi-
tive22, thus, in the absence of the effect on bacterial fitness, it would be more successful to add a change in a new 
position than to vary the amino acid at position 91. The presence of Gly at position 95 slightly affects the hydro-
phobicity pattern, but mainly affects the pattern of charges at this area, avoiding the interaction with radical 7 of 
the quinolones44.
This is the first description of a GyrB amino acid substitution Glu-475 → Lys in B. bacilliformis. The same 
amino acid change at the equivalent position of S. pneumoniae (Glu-474) has been associated with quinolone 
resistance45. Moreover, in S. pneumoniae a series of amino acid changes including Glu-476 → Ala and Arg-
477 → His has also been described in the same region, showing the relevance of the GyrB region in the devel-
opment of quinolone-resistance46,47. The 57.19Cip-5St mutant showed a MIC of 1.5 mg/L (3.95-fold higher than its 
parental isolate). Thus, by itself the Glu-475 → Lys alteration results in a slight increase in the CIP MIC. Moreover, 
this finding, together with the lack of PAβ N and ART effect on the CIP MIC, highlight the presence of unstable 
mechanism/s of resistance in the 57.19Cip-35 mutant.
Rifamycin-resistant rpoB gene mutations are usually located within 3 highly conserved regions in the mid 
portion of the gene. In E. coli these regions include codons 505–537 (cluster I), 563–575 (cluster II) and 684–690 
(cluster III)48,49. In the present study, the amino acid codon changes Gln-527 → Arg; His-540 → Tyr; 
Ser-545 → Phe are located within the B. bacilliformis equivalent cluster I, while Ser-588 → Tyr is located within the 
equivalent cluster II. Of these, the amino acid change Ser-545-Phe has been previously observed in B. bacilliformis 
and B. quintana in vitro RIF-resistant mutants18. However, substitutions at equivalent amino acid positions have 
been observed as being involved in the development of rifamycin resistance in other microorganisms including 
Mycobacterium tuberculosis50. Thus, in E. coli RpoB substitutions of Gln-513, His-526, Ser-531 or Ser-574 (equiv-
alents to Gln-527, His-540, Ser-545 and Ser-588 of B. bacilliformis respectively) have been described; moreover, 
in some cases the same amino acid change (e.g. Ser-531 → Phe or His-526 → Tyr) has also been reported43,51,52. 
In one case (57.20Rif-35) a double mutation (Ser-545 → Phe plus Ser-588 → Tyr) was observed. However, when the 
presence of an RpoB alteration was sought in 57.20Rif at passage 13, only the presence of the amino acid change 
Ser-588 → Tyr was observed. This fact shows the sequential selection of RIF resistance related to continuous anti-
biotic pressure. In E. coli the substitution at Ser-574 (equivalent to Ser-588) results in low-levels of RIF resistance, 
being its effect strongly diminished in the presence of PAβ N51. Thus, the selection of a mutation conferring low 
RIF resistance levels is followed by that of another additive mechanism of resistance, leading to an increase in the 
RIF resistance levels. Similarly, although substitutions at the equivalent Ser-545 position seem to result in high 
RIF MIC levels in E. coli49, in other microorganisms such as Rhodococcus equi only low levels of RIF resistance 
are conferred53.
This is the first determination of the role of efflux pumps in the development of antibiotic resistance in 
B. bacilliformis. The two EPI tested act differently, while PAβ N competes with other efflux pump substrates to be 
extruded from bacteria, ART diminishes the expression levels of some efflux pump encoding genes54,55. These 
differences may underlie the disparity of results obtained in the present study with these inhibitors.
Both PAβ N and ART affected the susceptibility levels of 57.18Azm-35 and 57.18Chl-40 mutants. In the first case 
the mutant presented L4 Δ 62–65. Although related to deletions in L22, a similar scenario has been observed in 
E. coli strains carrying 3 amino acid deletions in L22 in which the inactivation of different efflux pump compo-
nents results in a strong decrease in the erythromycin MIC levels56. Thus, it has been proposed that deletions at 
L22 alter the translation of specific proteins, possibly via changes in programmed stalling, modifying the cell 
envelope and resulting in efflux pump overexpression and lowering steady-state macrolide levels56. It is of interest 
to note that in 57.18Azm-35, the use of PAβ N was only visible in the disc diffusion analysis. The most probable sce-
nario for this is that the MIC of this strain is much higher than 256 mg/L and thus, the effect on the MIC levels, 
albeit present, was not observed. Regarding the 57.18Chl-40 mutant both the effect of PAβ N and ART decreased 
the CHL MIC levels to only slightly higher than the parental isolate, showing that efflux pumps may play a role 
in the development of low levels of CHL resistance in B. bacilliformis. No effect was observed with any inhibitor 
tested in either 57.19Chl-35 or 57.20Chl-40. This finding, together with the effect of ART on the antimicrobial sus-
ceptibility levels of all remaining 57.20 derivative mutants, highlight two facts: (a) the high levels of resistance to 
CHL derived from the presence of 23S rRNA mutations which when present mask the effect of efflux pumps, and 
(b) the presence of efflux pumps able to extrude the 4 antimicrobial families tested in B. bacilliformis. Thus, the 
different level of antimicrobial resistance of each selected mechanism may allow or not visualization of the over-
expression of efflux pumps and might underlie the differences in the effect of ART on the RIF-selected mutants. 
ART also affects the susceptibility to RIF in 57.19Rif-35 and 57.20Rif-35 mutants, showing that efflux pumps may also 
affect this antibiotic in B. bacilliformis and reinforcing the possibility that the selection of a double RpoB substi-
tution in the 57.20Rif-35 mutant was due to the low level of RIF resistance conferred. In the case of the 57.19Rif-35 
mutant the effect was only observed on the MIC levels, while in the case of 57.20Rif-35 the effect was observed in 
the disc diameter halo. Further studies are needed to determine the mechanisms of efflux pump overexpression 
(alterations in signal patterns, punctual mutations in promoter regions, among others).
In summary, the present data highlight the ability of B. bacilliformis to become antibiotic resistant both by the 
development of antibiotic-target alterations, but also mediated by efflux pump overexpression. However, regarding 
AZM, CHL and CIP, the instability of resistance detected in different mutants, either related to reversions and/or 
to dilution within a higher fitness susceptible population, suggests a high biological cost, which may underlie the 
rarity of antibiotic-resistant B. bacilliformis clinical isolates. Further studies analysing antibiotic target sequences 
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from a relevant number of B. bacilliformis clinical isolates prior, during and after antibiotic treatment are neces-
sary to better understand the natural history of antibiotic resistance in this microorganism.
Methods
Microorganisms. Three B. bacilliformis strains from the Institute Pasteur (Paris, France) collection were used 
(Table 5). The strains were reactivated following the instructions of the Institute Pasteur. Briefly, after opening, 
0.2 ml of LB was added to the vial to resuspend the bacteria. Thereafter, the suspension was spread onto Columbia 
blood agar (Ref: 254005, BD, Heidelberg, Germany) and incubated at 28 °C. The plates were inspected weekly 
until bacterial growth was observed. Prior to the development of the antibiotic resistant mutants, the bacterial 
identity of all three isolates was confirmed by amplification and sequencing of the 16S rRNA gene (Table 6)59.
In vitro development of resistant mutants. The antibiotic resistant mutants were selected by plating the 
B. bacilliformis on blood agar with a disc of AZM (15 μ g), CIP (5 μ g), CHL (30 μ g) or RIF (30 μ g) (BD, Franklin 
Lakes, USA) which was initially put in the corner of each plate, and subsequently in the center of the plate accord-
ing to halo diameter18. The confluent growth outside the zone of inhibition was recovered with a pre-sterilized 
plastic inoculation loop and subcultured 35 consecutive times. In those cases in which no halo zero was obtained, 
the isolates were grown in the presence of antibiotic for 5 additional passages.
At the beginning of the study, the passages with the selected antibiotic discs were performed every other 
week because of the difficulty to visualise the bacterial growth in the first weeks due the large halo sizes. Then, we 
changed to a weekly basis, according to the evolution of each strain.
Throughout the text, the mutants obtained are referred to by indicating the name of the parental isolate, the 
antibiotic used in its selection and the passage number (e.g.: 57.18Azm-35 is the AZM resistant mutant derived from 
strain 57.18 at passage 35).
Stability of resistance. Resistance stability was assessed by doing 5 final additional passages on Columbia 
blood agar, on a weekly basis, in the absence of antibiotic pressure. These are referred to in the text following the 
above mentioned nomenclature but including “5st” (5 serial passages to determine stability instead of passage 
number). When a mixed bacterial population was obtained (e.g.: growth of isolated colonies inside the inhibitory 
halo), isolates from inside of halo were additionally marked as “WH” (within halo).
Antibiotic susceptibility levels. The MICs of AZM, CIP, CHL and RIF of the parental isolates, the mutants 
at the final passage and after the 5 additional passages without antibiotic were determined by E-test (Liofilchem, 
IZASA, Barcelona, Spain). The MICs were read at 7 and 14 days. To determine the effect on the MIC levels the 
quotient MICF (final MIC)/MICI (initial MIC) was used. In all cases MIC differences > 2-fold were considered 
as significant.
Antibiotic cross resistance. In the final passage in the presence of antibiotic discs, antibiotic cross resist-
ance was determined by testing the MIC of each mutant with all the other antibiotics under study.
DNA extraction. B. bacilliformis were collected by adding sterile PBS into the plates and suspending the 
colonies with a one-use loop. This bacterial suspension was transferred to a sterile vial and the DNA was extruded 
by boiling at 100 °C for 10 minutes and stored at − 20 °C until use.
Target mutation detection. The presence of mutations in the rplV and rplD genes (AZM) as well as in 
the 23S rRNA (AZM and CHL), quinolone resistance-determining regions (QRDR) of the gyrA, gyrB, parC and 
parE genes (CIP) and the rpoB gene (RIF) were determined by PCR using the primers and conditions listed in 
Table 6. The PCR products were purified using a commercial kit according to the manufacturer’s instructions (Gel 
Extraction Kit from Omega Bio-tek, Georgia, USA) and thereafter sequenced (Beckman Coulter, Takeley, United 
Kingdom). The sequences obtained were compared with those of their respective parental strains and with that 
of the type strain KC583 (http://www.bacterio.net/bartonella.html). In cases in which the presence of non-silent 
mutations was observed, the deduced amino acid sequence was compared against B. bacilliformis amino acid 
sequences present in GenBank. Regarding GyrA, hydrophobicity was determined using the method of Kyte and 
Doolittle as defined in the ProtScale software60,61, while the polarity pattern was determined using the charge 
software (http://www.bioinformatics.nl/cgi-bin/emboss/charge).
Throughout the text, both the DNA and amino acid numeration is referred to as that of B. bacilliformis KC583. 
When DNA or amino acid positions of other microorganisms are used for comparison purposes this is explicitly 
indicated.
Strain E.D. Clonal
CIP NCTC1 Original1 Year1 Place Source1 AFLP2 ISR2 Ref.
57.18 12134 267 1949 Lima Blood B 2 57
57.19 12135 529 1941 NK NK B 2 57
57.20 12136 CPX 1957 NK Blood B 2 58
Table 5.  Parental isolates characteristics. E.D.: Epidemiological data; Original: Name of the original 
isolate. AFLP: Amplified Fragment Length Polymorphism; ISR: Intergenic Spacer Regions; Ref: Older 
reference including these strains that we found. NK: Not known. 1Information present in http://www.phe-
culturecollections.org.uk/. 2In Birtles et al.58.
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Role of Efflux Pumps. The role of efflux pumps in the development of antibiotic resistance was established 
by determining the antibiotic susceptibility levels by disc diffusion and E-test in commercial blood agar media 
supplemented in house with PAβ N, or ART. In order to determine the EPI concentrations to be used, the effect 
of different concentrations of these products (from 2.5 mg/L to 20 mg/L) on normal bacterial growth was tested. 
Additionally, the effect of 100% ethanol (ART solvent) was also independently assessed.
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